Towards newer molecular targets for chronic diabetic complications

Current Vascular Pharmacology

Volumn 4, Issue 1, 2006, Pages 45-57

  Khan, Zia A ^a,b   Farhangkhoee, Hana ^a   Chakrabarti, Subrata ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Advanced glycation end products; Aldose reductase; Diabetes; Endothelin; Fibronectin; Oxidative stress; Protein kinase C

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALDEHYDE REDUCTASE; AMINOGUANIDINE; BOSENTAN; CAVEOLIN 1; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; MOLSIDOMINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLACEBO; POLYOL; PROTEIN KINASE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; VASCULOTROPIN; ANTIDIABETIC AGENT;

CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; ENZYME ACTIVATION; GLYCATION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; KIDNEY; LIFE EXPECTANCY; MICROALBUMINURIA; MICROVASCULARIZATION; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL NERVE; RETINA; REVIEW; VASOCONSTRICTION; VASODILATATION; ANIMAL; DRUG DELIVERY SYSTEM; METABOLISM; MOLECULAR BIOLOGY; PHYSIOLOGY;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MOLECULAR BIOLOGY; OXIDATIVE STRESS;

EID: 33644851090     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016106775203081     Document Type: Review

References (156)

1. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey. Diabetes Care 1998-1994; 21: 518-54.
2. International Diabetes Federation. Diabetes Atlas, Second Edition. International Diabetes Federation; Brussells; 2003.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 29: 977-86.
4. Aleksandrovski YA. Molecular mechanisms of diabetic complications. Biochemistry (Mosc) 1998, 63: 1249-1257.
5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2000; 414: 813-20.
6. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288: 2579-88.
7. Engerman R, Bloodworth JM, Nelson S. Relationship of microvascular disease in diabetes to metabolic control. Diabetes 1985; 26: 760-9.
8. Strojek K. Features of macrovascular complications in type 2 diabetic patients. Acta Diabetol 2003; 40: S334-7.
9. Khan ZA, Chakrabarti S. Endothelins in chronic diabetic complications. Can J Physiol Pharmacol 2003; 81: 622-34.
10. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002; 106: 1783-7.
11. Blochl-Daum B, Vierhapper H, Eichler HG, Waldhausl W. Endothelin-induced venoconstriction is unaffected by type 2-diabetes: in vivo effect of histamine on the endothelin action on veins. Arch Int Pharmacodyn Ther 1992; 316: 90-6.
12. Yi Y, Baoyu W, Shenyuan Y, Liangxiang Z, Hanqing F, Yuantao L. Changes of nailfold microcirculation in patients of type II diabetes mellitus with diabetic retinopathy. Chin Med Sci J 1999; 14: 233-6.
13. Irving RJ, Walker BR, Noon JP, Watt GC, Webb DJ, Shore AC. Microvascular correlates of blood pressure, plasma glucose, and insulin resistance in health. Cardiovasc Res 2002; 53: 271-6.
14. Yuan S, Liu Y, Zhu L. Vascular complications of diabetes mellitus. Clin Exp Pharmacol Physiol 1999; 26: 977-8.
15. Zhu L. Gastric mucosal blood flow and blood viscosity in patients with diabetes. Zhonghua Yi Xue Za Zhi 1993; 73: 476-8.
16. van de Ree MA, Huisman MV, de Man FH, van der Vijver JC, Meinders AE, Blauw GJ. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res 2001; 52: 299-305.
17. Dogra G, Rich L, Stanton K, Watts GF. Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria. Diabetologia 2001; 44: 593-601.
18. Lambert J, Aarsen M, Donker AJ, Stehouwer CD. Endothelium-dependent and -independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16: 705-11.
19. Khan MA, Dashwood MR, Mumtaz FH, Thompson CS, Mikhailidis DP, Morgan RJ. Upregulation of endothelin A receptor sites in the rabbit diabetic kidney: potential relevance to the early pathogenesis of diabetic nephropathy. Nephron 1999; 83: 261-7.
20. Mumtaz FH, Dashwood MR, Khan MA, Thompson CS, Mikhailidis DP, Morgan RJ. Down-regulation of nitric oxide synthase in the diabetic rabbit kidney: potential relevance to the early pathogenesis of diabetic nephropathy. Curr Med Res Opin 2004; 20: 1-6.
21. Ahlborg G, Weitzberg E, Lundberg JM. Circulating endothelin-1 reduces splanchnic and renal blood flow and splanchnic glucose production in humans. J Appl Physiol 1995; 79: 141-5.
22. Pernow J, Kaijser L, Lundberg JM, Ahlborg G. Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 1996; 94: 2077-82.
23. Ahlborg G, Ottosson-Seeberger A, Hemsen A, Lundberg JM. Big ET-1 infusion in man causes renal ET-1 release, renal and splanchnic vasoconstriction, and increased mean arterial blood pressure. Cardiovasc Res 1994; 28: 1559-63.
24. Deng D, Evans T, Mukherjee K, Downey D, Chakrabarti S. Diabetes-induced vascular dysfunction in the retina: role of endothelins. Diabetologia 1999; 42: 1228-34.
25. Cukiernik M, Mukherjee S, Downey D, Chakabarti S. Heme oxygenase in the retina in diabetes. Curr Eye Res. 2003; 27: 301-8.
26. Riihimaa PH, Suominen K, Tolonen U, Jantti V, Knip M, Tapanainen P. Peripheral nerve function is increasingly impaired during puberty in adolescents with type 1 diabetes. Diabetes Care 2001; 24: 1087-92.
27. Duck SC, Wei FF, Parke J, Swick HM. Role of height and glycosylated hemoglobin in abnormal nerve conduction in pediatric patients with type I diabetes mellitus after 4-9 yr of disease. Diabetes Care 1991; 14: 386-92.
28. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44: 1973-88.
29. Cameron NE, Cotter MA. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 1994; 10: 189-224.
30. Cameron NE, Cotter MA. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabetes Res Clin Pract 1999; 45: 137-46.
31. Cameron NE, Dines KC, Cotter MA. The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin diabetic rats. Diabetologia 1994; 37: 1209-15.
32. Stevens EJ, Tomlinson DR. Effects of Endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes. Br J Pharmacol 1995; 115: 373-9.
33. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003; 254: 45-66.
34. Mogensen CE. Systemic blood pressure and glomerular leakage with particular reference to diabetes and hypertension. J Intern Med 1994; 235: 297-316.
35. Ritz E. Albuminuria and vascular damage - the vicious twins. N Engl J Med 2003; 348: 2349-52.
36. Drummond K, Mauer M. International Diabetic Nephropathy Study Group. The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 2002; 51: 1580-7.
37. Andersen S, Jacobsen P, Tarnow L, Rossing P, Juhl TR, Parving HH. Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Nephrol Dial Transplant 2003; 18: 293-7.
38. Buter H, Navis G, Dullaart RP, de Zeeuw D, de Jong PE. Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrol Dial Transplant 2001; 16: 771-5.
39. Turner NC, Morgan PJ, Haynes AC, Vidgeon-Hart M, Toseland N, Clapham JC. Elevated renal endothelin-1 clearance and mRNA levels associated with albuminuria and nephropathy in non-insulin dependent diabetes mellitus studies in obese fa/fa Zucker rats. Clin Sci 1997; 93: 565-71.
40. Panus C, Mota M, Vladu D, Vanghelie L, Raducanu CL. The endothelial dysfunction in diabetes mellitus. Rom J Intern Med 2003; 41: 27-33.
41. Deedwania PC. Diabetes is a vascular disease: the role of endothelial dysfunction in pathophysiology of cardiovascular disease in diabetes. Cardiol Clin 2004; 22: 505-9.
42. Lorenzi M, Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia 2001; 44: 791-804.
43. Archer DB. Diabetic retinopathy: some cellular, molecular and therapeutic considerations. Eye 1999; 13: 497-523.
44. Lobo CL, Bernardes RC, Figueira JP, de Abreu JR, Cunha-Vaz JG. Three-year follow-up study of blood-retinal barrier and retinal thickness alterations in patients with type 2 diabetes mellitus and mild nonproliferative diabetic retinopathy. Arch Ophthalmol 2004; 122: 211-7.
45. Cunha-Vaz J, Lobo C, Sousa JC, Oliveiros B, Leite E, de Abreu JR. Progression of retinopathy and alteration of the blood-retinal barrier in patients with type 2 diabetes: a 7-year prospective follow-up study. Graefes Arch Clin Exp Ophthalmol 1998; 236: 264-8.
46. O'Hare JA, Ferriss JB, Twomey B, O'Sullivan DJ. Poor metabolic control, hypertension and microangiopathy independently increase the transcapillary escape rate of albumin in diabetes. Diabetologia 1983; 25: 260-3.
47. Khan ZA, Chakrabarti S. Growth factors in proliferative diabetic retinopathy. Exp Diabesity Res 2003; 4: 287-301.
48. Ljubimov AV, Burgeson RE, Butkowski RJ, Couchman JR, Zardi L, Ninomiya Y, et al. Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histchem Cytochem 1996; 44: 1469-79.
49. Evans T, Deng DX, Chakrabarti S. Endothelin receptor blockade prevents augmented extracellular matrix protein component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose fed rats. Diabetes 2000; 49: 662-6.
50. Roy S, Cagliero E, Lorenzi M. Fibronectin overexpression in retinal microvessels of patients with diabetes. Invest Ophthalmol Vis Sci 1996; 37: 258-66.
51. Chen S, Khan ZA, Cukiernik M, Chakrabarti S. Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol Endocrinol Metab 2003; 284: E1089-97.
52. Fukuda G, Khan ZA, Barbin YP, Farhangkhoee H, Tilton RG, Chakrabarti S. Endothelin-mediated remodeling in aortas of diabetic rats. Diabetes Metab Res Rev 2004; [Epub ahead of print]
53. Chen S, Mukherjee S, Chakraborty C, Chakrabarti S. High glucose-induced, endothelin-1 dependent fibronectin synthesis is mediated via NF-κB and AP-1. Am J Physiol Cell Physiol 2003; 284: C263-72.
54. Khan ZA, Cukiernik M, Gonder JR, Chakrabarti S. Oncofetal fibronectin in diabetic retinopathy. Invest Ophthalmol Vis Sci 2004; 45: 287-95.
55. Xin X, Khan ZA, Chen S, Chakrabarti S. Extracellular signal-regulated kinase (ERK) in glucose-induced and endothelinmediated fibronectin synthesis. Lab Invest 2004; 84: 1451-9.
56. Isono M, Cruz MC, Chen S, Hong SW, Ziyadeh FN. Extracellular signal-regulated kinase mediates stimulation of TGF-beta1 and matrix by high glucose in mesangial cells. J Am Soc Nephrol 2000; 11: 2222-30.
57. Nishikawa T, Giardino I, Edelstein D, Brownlee M. Changes in diabetic retinal matrix protein mRNA levels in a common transgenic mouse strain. Curr Eye Res 2000; 21: 581-7.
58. Spirin KS, Saghizadeh M, Lewin SL, Zardi L, Kenney MC, Ljubimov AV. Basement membrane and growth factor gene expression in normal and diabetic human retinas. Curr Eye Res 1999; 18: 490-9.
59. Ljubimov AV, Burgeson RE, Butkowski RJ, Couchman JR, Zardi L, Ninomiya Y, et al. Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histochem Cytochem 1996; 44: 1469-79.
60. Kinoshita JH, Nishimura C. The involvement of aldose reductase in diabetic complications. Diabetes Metab Rev 1988; 4: 323-37.
61. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 1998; 50: 21-33.
62. Greene DA, Chakrabarti S, Lattimer SA, Sima AA. Role of sorbitol accumulation and myo-inositol depletion in paranodal swelling of large myelinated nerve fibers in the insulin-deficient spontaneously diabetic bio-breeding rat. Reversal by insulin replacement, an aldose reductase inhibitor, and myo-inositol. J Clin Invest 1987; 79: 1479-85.
63. Chakrabarti S, Sima AA. The effect of myo-inositol treatment on basement membrane thickening in the BB/W-rat retina. Diabetes Res Clin Pract 1992; 16: 13-7.
64. Greene DA, Stevens MJ. In: Ed LeRoith D, Taylor S, Olefsky J. The sorbitol-osmotic and sorbitol-redox hypotheses. In: Diabetes Mellitus. Philadelphia, Lippincott-Raven Publishers. 1996; 801-9.
65. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, et al. Perspectives in Diabetes. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801-13.
66. Trueblood N, Ramasamy R. Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. Am J Physiol 1998; 275: H75-83.
67. Sivenius K, Niskanen L, Voutilainen-Kaunisto R, Laakso M, Uusitupa M. Aldose reductase gene polymorphisms and susceptibility to microvascular complications in Type 2 diabetes. Diabet Med 2004; 21: 1325-33.
68. Wang Y, Ng MC, Lee SC, So WY, Tong PC, Cockram CS, et al. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 2003; 26: 2410-5.
69. Demaine AG. Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications. Curr Med Chem 2003; 10: 1389-98.
70. Costantino L, Rastelli G, Vianello P, Cignarella G, Barlocco D. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches. Med Res Rev 1999; 19: 3-23.
71. Engerman RL, Kern TS, Garment MB. Capillary basement membrane in retina, kidney, and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition. J Diabetes Complications 1993; 7: 241-5.
72. Sorbinil Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990; 108: 1234-44.
73. Suzen S, Buyukbingol E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr Med Chem 2003; 10: 1329-52.
74. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258: 607-14.
75. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-66.
76. Huang Q, Yuan Y. Interaction of PKC and NOS in signal transduction of microvascular hyperpermeability. Am J Physiol 1997; 273: H2442- 51.
77. Pomero F, Allione A, Beltramo E, Buttiglieri S, D'Alu F, Ponte E, et al. Effects of protein kinase C inhibition and activation on proliferation and apoptosis of bovine retinal pericytes. Diabetologia 2003; 46: 416-9.
78. Park JY, Takahara N, Gabriele A, Chou E, Naruse K, Suzuma K, et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 2000; 49: 1239-48.
79. Idris I, Gray S, Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 2001; 44: 659-73.
80. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992; 89: 11059-63.
81. Knott RM, Keenan FE, Muckersie E, Robertson M, Forrester JV. Glucose-dependent decreased DNA synthesis in bovine retinal endothelial cells is mediated by protein kinase C iota. Biochem Soc Trans 1998; 26: S260.
82. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-31.
83. Kowluru RA, Jirousek MR, Stramm L, Farid N, Engerman RL, Kern TS. Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases. Diabetes 1998; 47: 464-9.
84. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998; 39: 171-9.
85. Demolle D, de Suray JM, Onkelinx C. Pharmacokinetics and safety of multiple oral doses of LY333531, a PKC beta inhibitor, in healthy subjects. Clin Pharm Ther 1999; 65: 189.
86. Demolle D, de Suray JM, Vandenhende F. LY333531 single escalating oral dose study in healthy volunteers. Diabetologia 1998; 41: A354.
87. Aiello LP, Bursell S, Devries T. Protein kinase C beta selective inhibitor LY333531 ameliorates abnormal retinal haemodynamics in patients with diabetes. Diabetes 1999; 48: A19.
88. Milton R, Aiello L, Davis M, Sheetz M, Arora V, Vignati L. Initial results of the Protein Kinase C b Inhibitor Diabetic Retinopathy Study (PKC-DRS). Diabetes 2003; 52: A127.
89. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997; 46: S19-25.
90. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001; 17: 436-43.
91. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37: 586-600.
92. Takagi Y, Kashiwagi A, Tanaka Y, Asahian T, Kikkawa R, Shigeta Y. Significance of fructose-induced protein oxidation and formation of advanced glycation end product. J Diabetes Comp 1995; 9: 89-91.
93. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995; 270: 10017-26.
94. Stitt AW, He C, Vlassara H. Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biochem Biophys Res Commun 1999; 256: 549-56.
95. Stitt AW, Li YM, Gardiner TA, Bucala R, Archer DB, Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 1997; 150: 523-31.
96. Blakesley VA, Lerother D. In: Ed LeRoith D, Taylor S, Olefsky J. The role of growth factors in the pathogenesis of diabetic vascular complications, Diabetes Mellitus. Philadelphia, Lippincott-Raven. 1996; 824-81.
97. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogawa S, et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996; 45: S77-80.
98. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 2001; 50: 1636-42.
99. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP. The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors 1999; 10: 157-67.
100. Esposito C, Gerlach H, Brett J. Endothelial receptor mediated binding of glucose modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1992; 170: 1387-97.
101. Yamagishi S, Yonekura H, Yamamoto Y, Katsuno K, Sato F, Mita I, et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997; 272: 8723-30.
102. Vasan S, Foiles PG, Founds HW. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin Investig Drugs 2001; 10: 1977-87.
103. Xu X, Li Z, Luo D. Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: a factor in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2003; 241: 56-62.
104. Kalfa TA, Gerritsen ME, Carlson EC, Binstock AJ, Tsilibary EC. Altered proliferation of retinal microvascular cells on glycated matrix. Invest Ophthalm Vis Sci 1995; 36: 2358-67.
105. Son SM, Whalin MK, Harrison DG, Taylor WR, Griendling KK. Oxidative stress and diabetic vascular complications. Curr Diab Rep 2004; 4: 247-52.
106. King GL, Loeken MR. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol 2004; 122: 333-8.
107. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-9.
108. Wolff SP. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 1993; 49: 642-52.
109. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
110. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2000; 97: 12222-6.
111. Zafari AM, Ushio-Fukai M, Akers M, Shah A, Harison DG, Taylor WR, et al. Role of NADH/NADPH oxidase-derived H2 O2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998; 32: 488-95.
112. Warnholtz A, Nickening G, Schultz E. Increased NADH oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the reninangiotensin system. Circulation 1999; 99: 2027-33.
113. Decker P, Muller S. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol 2002; 3: 275-83.
114. Obrosova IG, Pacher P, Szabo C, Zsengeller Z, Hirooka H, Stevens MJ, et al. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 2005; 54: 234-42.
115. Soriano FG, Virag L, Szabo C. Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med 2001; 79: 437-48.
116. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001; 7: 108-13.
117. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 2001; 89: 684-91.
118. Farhangkhoee H, Khan ZA, Mukherjee S, Cukiernik M, Barbin YP, Karmazyn M, et al. Heme oxygenase in diabetes-induced oxidative stress in the heart. J Mol Cell Cardiol 2003; 35: 1439-48.
119. Abu El-Asrar AM, Meersschaert A, Dralands L, Missotten L, Geboes K. Inducible nitric oxide synthase and vascular endothelial growth factor are colocalized in the retinas of human subjects with diabetes. Eye 2004; 18: 306-13.
120. Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 2002; 90: 40L-48L.
121. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986; 250: H822-7.
122. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91: 2546-51.
123. Farhangkhoee H, Khan ZA, Chen S, Barbin YP, Feng Q, Chakrabarti S. eNOS-caveolin-CD36 axis in diabetes-induced oxidative stress. Can J Diabetes 2004; 28: A128.
124. Swerlick RA, Lee KH, Wick TM, Lawley TJ. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol 1992; 148: 78-83.
125. Khan ZA, Fukuda G, Cukiernik M, Chakrabarti S. Endothelin-mediated upregulation of CD36 in target organs of chronic diabetic complications. Can J Diabetes 2003; 27: A248.
126. Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA 1989; 86: 1046-50.
127. Ryter SW, Tyrrell RM. The heme synthesis and degradation pathways: role in oxidant sensitivity. Heme oxygenase has both pro-and antioxidant properties. Free Radic Biol Med 2000; 28: 289-309.
128. Khan ZA, Barbin YP, Cukiernik M, Adams PC, Chakrabarti S. Heme-oxygenase-mediated iron accumulation in the liver. Can J Physiol Pharmacol 2004; 82: 448-56.
129. Kowluru RA, Kern TS, Engerman RL, Armstrong D. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III. Effects of antioxidants. Diabetes 1997; 45: 1233-7.
130. Sobal G, Menzel J, Sinzinger H. Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study. Prostaglandins Leukot Essent Fatty Acids 2000; 63: 177-86.
131. Sharpe PC, Liu WH, Yue KK, McMaster D, Catherwood MA, McGinty AM, et al. Glucose-induced oxidative stress in vascular contractile cells: comparison of aortic smooth muscle cells and retinal pericytes. Diabetes 1998; 47: 801-9.
132. Kawamura N, Ookawara T, Suzuki K, Konishi K, Mino M, Taniguchi N. Increased glycated Cu,Zn-superoxide dismutase levels in erythrocytes of patients with insulin-dependent diabetis mellitus. J Clin Endocrinol Metab 1992; 74: 1352-4.
133. Smulders RA, Stehouwer CD, Olthof CG, van Kamp GJ, Teerlink T, de Vries PM, et al. Plasma endothelin levels and vascular effects of intravenous L arginine infusion in subjects with uncomplicated insulin dependent diabetes mellitus. Clin Sci 1994; 87: 37-43.
134. Collier A, Leach JP, McLellan A, Jardine A, Morton JJ, Small M. Plasma endothelinlike immunoreactivity levels in IDDM patients with microalbuminuria. Diabetes Care 1992; 15: 1038-40.
135. Chen S, Apostolova M, Cherian G, Charkrabarti S. Interaction of endothelin-1 with vasoactive factors in mediating glucose-induced increased permeability in endothelial cells. Lab Invest 2000; 80: 1311-21.
136. Bredt DS. Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic Res 1999; 31: 577-96.
137. Murad F. Cellular signaling with nitric oxide and cyclic GMP. Braz J Med Biol Res 1999; 32: 1317-27.
138. Woodman CR, Muller JM, Rush JW, Laughlin MH, Price EM. Flow regulation of ecNOS and Cu/Zn SOD mRNA expression in porcine coronary arterioles. Am J Physiol 1999; 276: H1058-63.
139. Tai SC, Robb GB, Marsden PA. Endothelial nitric oxide synthase: a new paradigm for gene regulation in the injured blood vessel. Arterioscler Thromb Vasc Biol 2004; 24: 405-12.
140. Li H, Wallerath T, Forstermann U. Physiological mechanisms regulating the expression of endothelial-type NO synthase. Nitric Oxide 2002; 7: 132-47.
141. Chen S, Khan ZA, Barbin Y, Chakrabarti S. Pro-oxidant role of heme oxygenase in mediating glucose-induced endothelial cell damage. Free Radic Res 2004; 38: 1301-10.
142. Gelinas DS, Bernatchez PN, Rollin S, Bazan NG, Sirois MG. Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. Br J Pharmacol 2002; 137: 1021-30.
143. Scotland RS, Morales-Ruiz M, Chen Y, Yu J, Rudic RD, Fulton D, Gratton JP, et al. Functional reconstitution of endothelial nitric oxide synthase reveals the importance of serine 1179 in endothelium-dependent vasomotion. Circ Res 2002; 90: 904-10.
144. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-5.
145. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hyper-cholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999; 103: 897-905.
146. Levin ER. Endothelins. N Engl J Med 1995; 333: 356-63.
147. Lum H, Malik AB. Mechanisms of increased endothelial permeability. Can J Physiol Pharmacol 1996; 74: 787-800.
148. Khan ZA, Barbin YP, and Chakrabarti S. Glucose-induced oncofetal fibronectin in angiogenesis and signal transduction in vascular endothelial cells. Diabetes 2004; 53: A443.
149. Tomlinson DR. Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabetologia 1999; 42: 1271-81.
150. Awazu M, Ishikura K, Hida M, Hoshiya M. Mechanisms of mitogen-activated protein kinase activation in experimental diabetes. J Am Soc Nephrol 1999; 10: 738-45.
151. Toyoda M, Suzuki D, Honma M, Uehara G, Sakai T, Umezono T, et al. High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney Int 2004; 66: 1107-14.
152. Fujita H, Omori S, Ishikura K, Hida M, Awazu M. ERK and p38 mediate high-glucose-induced hypertrophy and TGF-beta expression in renal tubular cells. Am J Physiol Renal Physiol 2004; 286: F120-6.
153. Price SA, Agthong S, Middlemas AB, Tomlinson DR. Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase. Diabetes 2004; 53: 1851-6.
154. Wold LE, Ren J. Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinase-dependent oxidative stress mechanism. Biochem Biophys Res Commun 2004; 318: 1066-71.
155. Xin X, Khan ZA, Chen S, Chakrabarti S. High glucose-induced protein kinse B mediates nuclear factor-kB activation and fibronectin expression in endothelial cells. Can J Diabetes 2004; 28: A200.
156. Barbin YP, Khan ZA, Norbert B, Scholz W, Chakrabarti S. Serum-and glucocorticoid-regulated kinase mediated, glucose-induced, fibronectin upegulation in endothelial cells. Diabetes 2004; 53: 86LB.